Latest From Amyris Inc.
This week's roundup includes two executive appointments by GSK, plus updates from Radius Health Inc., Cue Biopharma and BenevolentAI, with Myovant Sciences making four key management hires.
This week's roundup includes executive appointments by Gilead Sciences, Nordic Nanovector, Mereo BioPharma, vasopharm and Rigontec. Biogen has also appointed two executives to its planned spin-off company, Bioverativ.
Synthetic biology offers opportunity across many industries, but the ultimate prize may be health care. The millions of dollars investors have poured into companies developing CAR-T cell therapies and gene editing technologies points to growing confidence in the power of gene manipulation to generate novel, approvable therapeutics, even if for now these are just the early steps toward creating fully synthetic organisms.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2016.
- Synthesis Technologies, Production Processes
- Therapeutic Areas
- Amyris Biotechnologies Inc.
- North America
- Parent & Subsidiaries
- Amyris Inc.
- Senior Management
John G Melo, Pres. & CEO
Kathleen Valiasek, CFO
Joel Cherry, President, R&D
Cynthia Bryant, SVP, Corp. Dev.
- Contact Info
Phone: (510) 450-0761
5885 Hollis St.
Emeryville, CA 94608
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.